issued
on 02 Jan 2024
Last Applicant/ Owned by
Suite 6-401
Cambridge
MA
02139
Serial Number
97493218 filed on 07th Jul 2022
Registration Number
N/A
Correspondent Address
Tiffany D. Gehrke
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"BIO"
Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Research and development of pharmaceutical products; Research and development in the field of bioscience; Research and development of biomedical compounds comprised of nucleotide polymers for use in targeted pharmaceutical therapies for theRead More
Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Research and development of pharmaceutical products; Research and development in the field of bioscience; Research and development of biomedical compounds comprised of nucleotide polymers for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; Research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; Research and development of biomedical compounds comprised of nucleotide polymers for targeted RNA editing; Research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders
Custom manufacture of biomedical compounds comprised of nucleotide polymers or biomedical compounds comprised of ribonucleic acid polymers for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
Pharmaceutical preparations for the treatment of rare genetic diseases; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of ribonucleic acid polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in RNA editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in base editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases
No 97493218
No Service Mark
No 33791/60000
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 02th Jan 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 07th Nov 2023 | PUBLISHED FOR OPPOSITION |
| 07th Nov 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 18th Oct 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 30th Sep 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 29th Sep 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 29th Sep 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 29th Sep 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 28th Aug 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| 28th Aug 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
